Unreliable? 76% of world’s blood pressure monitors have not been validated

Seventy-six percent of the world’s blood pressure (BP) monitors have not been properly validated, according to a new analysis published in JAMA.[1] This raises questions as to what does this means for patient care?

“To identify and manage elevated BP, guidelines from hypertension societies recommend BP measurement using automated cuff-based devices that are clinically validated for accuracy,” wrote lead author Dean S. Picone, PhD, of the Menzies Institute for Medical Research at the University of Tasmania in Australia. “Validated devices are more likely to be accurate compared with devices without evidence of validation. However, regulations in most countries permit devices to be cleared for marketing without evidence of validation.”

Picone et al. explored a publicly available Medaval database, gathering information on nearly 4,300 BP monitors. Once exclusions were made for manually operated devices and devices that measure BP somewhere other than the patient’s upper arm or wrist, the group was left with 3,411 devices manufactured by 457 different companies. The devices are distributed throughout North America, South American, Asia, Europe, Africa and Oceania. Many are also sold online.

Researchers then searched for evidence that each device had passed a proper validation protocol. New devices with measurement technology “identical to that of previously validated devices” were viewed as being “equivalent,” meaning a separate validation was not required.

Overall, 8.8% of devices had been validated, 11.1% were equivalent and there was “no evidence of validation” for 76.3%. The remaining devices were either in the process of being audited by Medaval or the validation had failed.

Looking just at the study’s 2,486 upper arm cuff devices, 10% had been validated, 13.2% were equivalent and there was “no evidence of validation” for 73%. For the study’s 925 wrist-based devices, 5.6% had been validated, 5.5% were equivalent and there was “no evidence of validation” for 85%.

“A minority of automated upper arm cuff and wrist-based devices globally have evidence of validation for accuracy,” the authors wrote. “Lack of validation may undermine optimal medical practice through increased potential for incorrect hypertension diagnosis and inappropriate care. Global and national policy frameworks, including regulations with enforcement, are needed, with the goal that all devices meet minimum requirements for independent validation before premarket clearance.”

The Menzies Institute for Medical Research has published a guide that can help patients determine if a blood pressure monitor has been properly tested for accuracy. Click here for the full breakdown.

Related Heart Health Content:

Too much Tylenol? Daily acetaminophen use may be bad for hypertension patients

Recovered COVID-19 patients face higher risk of heart rate abnormalities, type 2 diabetes

'Psychoactive and harmful': World Heart Federation says alcohol is never good for the heart

 

Reference:

1. Dean S. Picone, PhD, Norm R. C. Campbell, MD, PhD, Aletta E. Schutte, PhD, et al. Validation Status of Blood Pressure Measuring Devices Sold Globally. JAMA. 2022;327(7):680-681. doi:10.1001/jama.2021.24464.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.